Medical News

RSS

DALSA launches its XRI-1600 digital image processor at the RSNA 2009

DALSA, a global leader in digital imaging technology, today announced the introduction of its XRI-1600 digital image processor, which is ideal for X-ray imaging applications. At RSNA 2009, the annual meeting of the Radiological Society of North America held at McCormick Place in Chicago, DALSA will be demonstrating the XRI-1600 at Booth #7117 (North Building, Hall B) from November 29 - December 4, 2009.

30 Nov 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

Sanofi-aventis U.S. announced today the signing of an exclusive licensing agreement with Intelliject, Inc. for a novel epinephrine auto injector for the emergency treatment of allergic reactions (anaphylaxis) in North America (U.S. and Canada).

30 Nov 2009

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Novavax, Inc. announced today it has completed enrollment in the Phase II clinical study of its trivalent seasonal influenza (2008/2009 recommended strains) VLP vaccine candidate in healthy adults 60 years of age or older (older adults). This randomized, double-blind, active-controlled study is comparing the safety, tolerability and immunogenicity of two different doses (15 mcg and 60 mcg) of Novavax's trivalent seasonal influenza VLP vaccine to a commercially available trivalent inactivated vaccine, TIV (Fluzone®).

30 Nov 2009

Top Maryland hospitals worry about effects of health reform

Leaders at Maryland's top hospitals worry about efforts to cut hospital costs in the health care reform proposals.

30 Nov 2009

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

MagForce Nanotechnologies AG has submitted the product file for NanoTherm® to Medcert GmbH, the medical certification and testing company which serves as Notified Body for the certification of medical products. With this step, MagForce has now commenced the conformity assessment procedure for its Nano-Cancer ® therapy.

30 Nov 2009

COBRA subsidy for many ends today, laid-off workers face bigger bills

As part of February's economic stimulus package, the federal government began subsidizing insurance premiums for millions of recently unemployed workers - such as Paul and Kate Carroll, whose story is highlighted in the Sacramento Bee. But for many people, the subsidies end Monday, leaving the laid-off workers to pay the full cost of insurance plans offered by their former employers if they wish to keep the coverage, the Bee reports.

30 Nov 2009

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Xencor, Inc., a company using Fc engineering for the discovery and development of next-generation and biosuperior antibodies, announced today that it has licensed its XmAb® and Xtend™ technology platforms to Centocor Research & Development, Inc. for the optimization of Centocor’s antibody drug candidates.

30 Nov 2009

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Bavarian Nordic A/S announced today that the company expects to file a New Drug Submission (NDS) for its third-generation smallpox vaccine, IMVAMUNE(R) with the Canadian Authorities, Health Canada in 2010. If successful, this would be the first marketing approval of IMVAMUNE(R).

30 Nov 2009

Kiadis Pharma commences enrollment in multinational ATIR study

Biopharmaceutical company Kiadis Pharma announces today that the first patients have been enrolled in its multinational registration clinical trial with ATIR(TM). The study is designed to show reduction in transplant related mortality (TRM) after one year following an allogeneic stem cell transplantation with a mismatched (haplo-identical) donor in blood cancer patients eligible for an allogeneic stem cell transplantation but without having a matched donor available.

30 Nov 2009

DALSA to showcase its Helios10 MD panel at the RSNA 2009

DALSA Corporation, through its Rad-icon Imaging division, today announced general availability of the Helios10 MD panel, the first product in the company's new Helios camera family. With an active area of 20 x 25 cm, the Helios10 MD is the first CMOS X-Ray panel from DALSA of this size and form factor, a medical-grade cassette package with an integrated handle.

30 Nov 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Allos Therapeutics, Inc. today announced that the United States Patent and Trademark Office has issued a patent for the use of FOLOTYN™ (pralatrexate injection) for the treatment of T-cell lymphoma. U.S. Patent No. 7,622,470 was issued to Memorial-Sloan Kettering Cancer Center, SRI International and Southern Research Institute, and expires on November 24, 2025.

30 Nov 2009

Eli Lilly's Cymbalta receives FDA approval

The U.S. Food and Drug Administration (FDA) has approved Cymbalta® (duloxetine HCl) for the maintenance treatment of generalized anxiety disorder (GAD) in adults, announced Eli Lilly and Company (NYSE: LLY).

30 Nov 2009

Acsys Interactive's recommendations to the FDA on social media in the healthcare industry

At the invitation of the Food and Drug Administration, Stan Valencis, President of Acsys Interactive, recently presented a series of recommendations to help shape the government's policy towards the promotion of prescription drugs, biologics and medical devices using the Internet and social media tools. As a leader in providing digital marketing and interactive strategies to healthcare systems, hospitals, device manufacturers and pharmaceutical companies, Acsys Interactive was selected by the FDA to provide its uniquely qualified perspective and experience.

30 Nov 2009

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

A multidisciplinary team from the Montreal Heart Institute (MHI) performed its first catheter implantation of a new prosthesis (Amptlazer(R) Cardiac Plug) closing the appendage of the left atrium of the heart, which will have the effect of preventing the formation of blood clots and avoiding open-heart surgery. This is excellent news for patients suffering from atrial fibrillation, the most common form of cardiac arrhythmia, affecting at least 5% of Canadians over the age of 70.

30 Nov 2009

NanoViricides announces filing of its quarterly report with the SEC

NanoViricides, Inc., reports that the Company has filed its quarterly report with the SEC on November 23rd.

30 Nov 2009

Covidien sells its Oxygen Therapy product line to Chart Industries

Covidien, a leading global provider of healthcare products, today announced that it had completed the previously announced sale of its Oxygen Therapy assets to Chart Industries, Inc.. Financial terms of the transaction were not disclosed.

From Chart Industries 30 Nov 2009

Micromet to present new results from its blinatumomab study at the ASH meeting

Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will present new results from its clinical studies with blinatumomab at the 51st annual meeting of the American Society of Hematology from December 5-8, 2009 in New Orleans, Louisiana.

30 Nov 2009

ALS research collaboration receives philanthropic funding

Three prominent philanthropic organizations – The Angel Fund, The ALS Therapy Alliance and Project ALS -- dedicated to finding a treatment for amyotrophic lateral sclerosis (ALS) have financed a new collaboration between one of the world’s leading ALS researchers and RXi Pharmaceuticals Corporation, a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi).

30 Nov 2009

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Spectrum Pharmaceuticals today announced that one of the two Phase 3 pivotal clinical trials of apaziquone has achieved its enrollment target, having enrolled approximately 800 patients with non-invasive bladder cancer. The second Phase 3 clinical trial of apaziquone is expected to complete enrollment by the end of the year.

30 Nov 2009

Gentium announces financial results for the third quarter ended September 30, 2009

Gentium S.p.A. today reported financial results for the quarter ended September 30, 2009.

30 Nov 2009

Medical News

DALSA launches its XRI-1600 digital image processor at the RSNA 2009

Sanofi-aventis, Intelliject sign an exclusive licensing agreement for novel epinephrine auto injector

NOVAVAX completes patient enrollment in its trivalent seasonal influenza VLP vaccine Phase II study

Top Maryland hospitals worry about effects of health reform

MagForce Nanotechnologies initiates conformity assessment procedure for its Nano-Cancer therapy

COBRA subsidy for many ends today, laid-off workers face bigger bills

Xencor licenses its XmAb and Xtend technology platforms to Centocor Research & Development

Bavarian Nordic to file a NDS for IMVAMUNE with Health Canada

Kiadis Pharma commences enrollment in multinational ATIR study

DALSA to showcase its Helios10 MD panel at the RSNA 2009

Allos Therapeutics granted U.S. patent for FOLOTYN

Eli Lilly's Cymbalta receives FDA approval

Acsys Interactive's recommendations to the FDA on social media in the healthcare industry

MHI team performs catheter implantation of the new Amptlazer Cardiac Plug prosthesis

NanoViricides announces filing of its quarterly report with the SEC

Covidien sells its Oxygen Therapy product line to Chart Industries

Micromet to present new results from its blinatumomab study at the ASH meeting

ALS research collaboration receives philanthropic funding

Spectrum Pharmaceuticals completes enrollment in apaziquone Phase 3 trial

Gentium announces financial results for the third quarter ended September 30, 2009

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News